CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) --BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietaryintranasal nose-to-brain (N2B) systemthat enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc.(NASDAQ: BIIB), Moderna Inc.(NASDAQ: MRNA), CytoDyn Inc.(OTCQB: CYDY) and Northwest Biotherapeutics Inc.(OTCQB: NWBO).

• Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.

• The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.

• Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.

• As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.

• The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.

Clickhereto view the custom infographic of the Oncotelic Therapeutics editorial.

The blood-brain barrier (BBB) is a highly selective membrane that protects the brain from toxins and pathogens circulating in the bloodstream. While essential for survival, it also presents a formidable obstacle for therapeutic development. Researchindicatesthat the BBB restricts the passage of most compounds, allowing only certain molecules to enter brain tissue. This protective function, while biologically beneficial, significantly limits the effectiveness of many drugs intended to treat neurological conditions.

Research consistently shows that the vast majority of therapeutics are unable to cross this barrier. Scientific consensussuggeststhat approximately 98% of small-molecule drugs and nearly all biologics fail to penetrate the BBB effectively, making CNS drug delivery one of the most persistent challenges in pharmaceutical development. This limitation contributes to the high failure rate seen in CNS drug pipelines, where promising compounds often fail, not due to lack of efficacy but because they cannot reach their intended targets in the brain.

The implications of this barrierextendacross a wide range of conditions, including Alzheimer’s disease, Parkinson’s disease and brain cancers. Despite decades of research and billions of dollars invested, treatment options for many CNS disorders remain limited. The inability to deliver therapeutics at effective concentrations to the brain continues to slow progress, underscoring the urgent need for innovative delivery approaches.

Within this context,Oncotelic Therapeuticsis focused on advancing technologies designed to bypass or overcome BBB limitations. Evidence of the company’s success is its recent announcement of the closing of a strategic monetization with Lunai Bioworks. According to the company, the transfer agreement is for Oncotelic’s N2B delivery system, establishing an initiative on biodefense and Alzheimer’s disease (AD).

“Under the terms of the agreement, Oncotelic has granted Lunai Bioworks worldwide rights to the N2B delivery system IP portfolio within defined fields, specifically biodefense medical countermeasures and Alzheimer’s disease only,” the announcement stated. “The company continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets.”

By prioritizing delivery mechanisms alongside therapeutic development, the company is aligning with a broader shift toward integrated solutions that address one of the most fundamental challenges in CNS medicine.

The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate. According to the World Health Organization,more than57 million people around the world are currently living with dementia,a number expected to rise significantly in the coming decades as populations age. This growing prevalence is placing immense strain on healthcare systems, caregivers and economies worldwide.

Despite the scale of the crisis, treatment progress has been incremental. The Alzheimer’s Associationnotesthat while there has been progress in understanding disease mechanisms and developing therapies, many drug candidates fail during clinical trials. One key reason is the difficulty in delivering sufficient drug concentrations to the brain, even when compounds show promise in preclinical models.

Recent developments from various companies highlight both progress and limitations in the field. Potential therapies have demonstrated clinical benefits, yet discussions around efficacy often point back to delivery challenges and the difficulty of achieving consistent therapeutic impact within the brain. These dynamicsreinforcethe idea that drug delivery remains a central issue in CNS innovation.

In this environment, Oncotelic Therapeutics is positioning itself within a segment of the marketfocusedon enabling more efficient brain delivery. By aligning with emerging trends in targeted delivery and precision medicine, the company is working within a space where addressing the delivery bottleneck could significantly improve outcomes across multiple neurodegenerative conditions.

Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security. Chemical and biologicalthreatscan directly impact the nervous system, requiring rapid intervention to prevent long-term damage or death. In these scenarios, the speed and effectiveness of drug delivery to the brain can determine survival outcomes.

Government agencies are increasingly prioritizing medical countermeasures capable of addressing such threats. The Biomedical Advanced Research and Development Authority (BARDA)playsa central role in funding and advancing technologies designed to respond to chemical, biological, radiological and nuclear threats. Similarly, the U.S. Department of Defense hasidentifiedneuroprotection and CNS injury response as key research priorities, reflecting the importance of rapid therapeutic intervention in high-risk scenarios.

These initiatives underscore the need for delivery systems that can act quickly and bypass traditional physiological barriers. In emergency settings, delays caused by inefficient drug delivery can significantly reduce treatment effectiveness. As a result, there is growing interest in technologies that enable direct-to-brain delivery, ensuring that therapeutics reach the CNS rapidly and at sufficient concentrations.

Oncotelic Therapeutics is operating within this evolving landscape byexploringapplications that extend beyond traditional disease treatment into biodefense and emergency response. This dual-use positioning, spanning both commercial healthcare and government-funded initiatives, reflects a broader trend toward versatile platforms capable of addressing multiple high-impact use cases.

As traditional drug-delivery approaches continue to face limitations,alternative methodsdesigned to bypass the BBB are gaining increasing attention. Among these, intranasal or “nose-to-brain” delivery has emerged as a promising pathway. This approach leverages neural connections between the nasal cavity and the brain to deliver therapeutics directly to CNS tissues.

Researchhighlightsthe potential of intranasal delivery systems to improve drug transport to the brain while minimizing systemic exposure. Studies suggest that this method can enhance bioavailability and reduce side effects, making it an appealing option for treating neurological conditions.

Industryanalysisfrom Deloitte further supports this trend, noting that innovation in CNS therapeutics is increasingly focused on delivery technologies rather than solely on new drug compounds. As pharmaceutical companies seek to improve clinical outcomes, the ability to deliver drugs more effectively is becoming a key differentiator.

Oncotelic’s N2B delivery system represents a device-enabled therapeutic approach designed to deliver agents directly to the central nervous system, offering a potential alternative to traditional intramuscular or systemic delivery methods. By bypassing the blood-brain barrier, the platform enables faster onset of action and improved targeting of neurological pathways critical in both acute biodefense scenarios and chronic neurodegenerative diseases.

The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies. These platforms are designed to support multiple therapies and indications, offering scalability and flexibility that traditional models often lack. This shift reflects a growing recognition that delivery technology can unlock value across a wide range of applications.

Platform-based approaches are particularly well suited to addressing the complexities of CNS disorders, where diverse conditions share common delivery challenges. By developing systems that can be adapted for different therapeutics, companies can create multiple pathways to commercialization while reducing reliance on any single asset. This model also aligns with trends in precision medicine, where targeted delivery plays a critical role in improving patient outcomes.

From an investment perspective,platform strategiesoffer several advantages. They enable diversification across multiple markets, including neurodegenerative diseases and biodefense applications, while also supporting partnerships and licensing opportunities. This combination of near-term monetization potential and long-term value creation is increasingly attractive in a sector known for high risk and long development timelines.

Oncotelic Therapeutics reflects this strategic direction through its focus on scalable delivery platforms that can support a range of CNS indications. By combining commercialization pathways with long-term development potential, the company is aligned with a broader industry shift toward solutions that address both the scientific and operational challenges of CNS therapeutics.

The challenge of delivering drugs to the brain remains one of the most significant barriers in modern medicine. As Alzheimer’s disease cases continue to rise and global attention turns toward biodefense preparedness, the need for faster, more effective CNS delivery solutions is becoming increasingly urgent. Addressing this challenge will require innovation not only in drug discovery but also in how therapies are delivered.

In this dynamic landscape, companies focused on overcoming the blood-brain barrier and enabling targeted delivery are positioned at the forefront of change. Oncotelic Therapeutics represents one example of this shift, operating within a broader movement toward platform-based solutions that aim to unlock new possibilities in CNS treatment. As the industry continues to evolve, the ability to deliver therapeutics efficiently to the brain may ultimately prove to be the defining factor in future medical breakthroughs.

Leading biopharma companies are increasingly focusing on cutting-edge therapeutic platforms designed to accelerate large-scale drug development across a broad range of treatment areas. Recent developments throughout the sector highlight growing investment in advanced modalities such as mRNA therapies, immune-targeting biologics, precision peptide technologies and cell-based platforms, reflecting an industry-wide push toward more scalable, adaptable and personalized approaches to treating complex diseases.

Biogen Inc.(NASDAQ: BIIB)announceda research collaboration with Dayra Therapeutics. The collaboration is designed to discover and develop oral macrocyclic peptides for priority targets in immunological conditions. According to the company, macrocyclic peptides have a unique profile with the potential to offer biologic-like efficacy and safety in an oral format, potentially disrupting established antibody-based treatments. The collaboration enhances Biogen’s strategy to build a differentiated immunology portfolio.Moderna Inc.(NASDAQ: MRNA)presenteddata from a phase 1/2 study of mRNA-4359 at the American Association for Cancer Research (AACR) annual meeting. The presentation on mRNA-4359, an investigational cancer antigen therapy, reported safety, efficacy and translational data from a phase 2 dose-expansion cohort of the phase 1/2 study, which evaluated mRNA-4359 + pembrolizumab as a first-line therapy in patients with locally advanced or metastatic melanoma. Consistent with mRNA-4359's mechanistic rationale, antigen-specific T-cell responses and novel expanded T-cell receptor (TCR) clonality was observed in all patients with evaluable samples.

CytoDyn Inc.(OTCQB: CYDY)presentednew preclinical, translational and clinical data at the AACR Immuno-Oncology Conference. The data supported leronlimab’s proposed role in the treatment of metastatic triple-negative breast cancer (mTNBC). Leronlimab is a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, mTNBC and colorectal cancer. Leronlimab is being evaluated for its ability to modulate the tumor immune microenvironment by targeting the CCR5 receptor, a key regulator of immune function implicated in cancer progression and immune resistance.

Northwest Biotherapeutics Inc.(OTCQB: NWBO) is establishing its own dedicated clinic for leukapheresis procedures at the London Welbeck Hospital. The company is doing so in order to proactively address potential constraints in available leukapheresis capacity. The company anticipates that this will facilitate scale-up of its programs and will also enable provision of these services for other parties

These significant milestones reflect a broader transformation in biotechnology, where innovative therapeutic platforms and immune-focused strategies are reshaping the future of disease treatment. As research progresses and clinical programs expand, the sector continues moving toward more personalized, scalable and targeted approaches designed to improve outcomes across oncology, immunology and other serious diseases.

For more information, visitOncotelic Therapeutics Inc.

BioMedWire(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within theDynamic Brand Portfolio@IBNthat delivers:(1) access to a vast network of wire solutions viaInvestorWireto efficiently and effectively reach a myriad of target markets, demographics and diverse industries;(2) article andeditorial syndication to 5,000+ outlets;(3) enhancedpress release enhancementto ensure maximum impact;(4)social media distributionvia IBN to millions of social media followers;and (5) a full array of tailoredcorporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visithttps://www.BioMedWire.comDISCLAIMER:BioMedWire (BMW)is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:https://www.BioMedWire.com/DisclaimerBioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.comBioMedWire is powered byIBN